MedPath
Found 302 clinical trials|View Analysis
Sort by:

Transoral Surgical Resection Followed by De-escalated Adjuvant IMRT in Resectable p16+ Locally Advanced Oropharynx Cancer

Phase 2
Recruiting
Conditions
Oropharynx Cancer
Interventions
Procedure: therapeutic conventional surgery
Other: laboratory biomarker analysis
Other: quality-of-life assessment
Radiation: intensity-modulated radiation therapy
Drug: Cisplatin
Drug: Carboplatin
First Posted Date
2022-05-24
Last Posted Date
2024-06-06
Lead Sponsor
Heath Skinner
Target Recruit Count
150
Registration Number
NCT05388773
Locations
🇺🇸

UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, United States

A Fluorescent Tumor Marking Agent, Tozuleristide, for Imaging Oral Cavity Squamous Cell Cancer and High-Grade Oral Cavity Dysplasia During Surgery

Phase 1
Recruiting
Conditions
Stage III Lip and Oral Cavity Cancer AJCC v8
Stage II Lip and Oral Cavity Cancer AJCC v8
Oral Cavity Squamous Cell Carcinoma
Stage I Lip and Oral Cavity Cancer AJCC v8
Stage IVA Lip and Oral Cavity Cancer AJCC v8
Interventions
Procedure: Near Infrared Imaging
Procedure: Therapeutic Conventional Surgery
Drug: Tozuleristide
First Posted Date
2022-04-07
Last Posted Date
2024-11-26
Lead Sponsor
University of Washington
Target Recruit Count
15
Registration Number
NCT05316688
Locations
🇺🇸

Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States

Investigating Targetable Metabolic Pathways Sustaining Pancreatic Cancer

Not Applicable
Recruiting
Conditions
Pancreatic Ductal Adenocarcinoma
Interventions
Procedure: Biopsy
Procedure: Therapeutic Conventional Surgery
Other: Uniformly-labeled [13C]glucose
First Posted Date
2022-03-25
Last Posted Date
2024-04-10
Lead Sponsor
Rutgers, The State University of New Jersey
Target Recruit Count
16
Registration Number
NCT05296421
Locations
🇺🇸

Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States

🇺🇸

Cooperman Barnabas Medical Center (Saint Barnabas Medical Center), Livingston, New Jersey, United States

Neoadj Admin Autologous Tumor Infiltrating Lymphocytes & Pembrolizumab for Treatment of Adv Melanoma Patients

Phase 1
Active, not recruiting
Conditions
Pathologic Stage IIIC Cutaneous Melanoma AJCC v8
Stage IV Melanoma
Locally Advanced Melanoma
Pathologic Stage IIIB Cutaneous Melanoma AJCC v8
Pathologic Stage IIID Cutaneous Melanoma AJCC v8
Interventions
First Posted Date
2022-01-04
Last Posted Date
2025-01-08
Lead Sponsor
Richard Wu
Target Recruit Count
2
Registration Number
NCT05176470
Locations
🇺🇸

Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States

Atezolizumab Before Surgery for the Treatment of Regionally Metastatic Head and Neck Squamous Cell Cancer With an Unknown or Historic Primary Site

Phase 2
Terminated
Conditions
Locally Advanced Cutaneous Squamous Cell Carcinoma of the Head and Neck
Resectable Cutaneous Squamous Cell Carcinoma of the Head and Neck
Stage III Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v8
Interventions
Biological: Atezolizumab
Radiation: Radiation Therapy
Procedure: Therapeutic Conventional Surgery
First Posted Date
2021-11-08
Last Posted Date
2023-09-05
Lead Sponsor
Arnaud Bewley, MD
Target Recruit Count
1
Registration Number
NCT05110781
Locations
🇺🇸

University of California Davis Comprehensive Cancer Center, Sacramento, California, United States

Feasibility Study of Anatomical Modeling for Image Guided Thoracic Surgery

Not Applicable
Completed
Conditions
Lung Neoplasm
Interventions
Procedure: Computed Tomography
Procedure: Therapeutic Conventional Surgery
First Posted Date
2021-09-16
Last Posted Date
2024-10-28
Lead Sponsor
M.D. Anderson Cancer Center
Target Recruit Count
3
Registration Number
NCT05046067
Locations
🇺🇸

M D Anderson Cancer Center, Houston, Texas, United States

Preoperative Radiosurgery for the Treatment of High Grade Glioma, NeoGlioma Trial

Phase 1
Recruiting
Conditions
Malignant Glioma
Interventions
Radiation: Radiation Therapy
Radiation: Radiosurgery
Procedure: Stereotactic Biopsy
Drug: Temozolomide
Procedure: Tumor Treating Fields Therapy
Procedure: Magnetic Resonance Imaging
Procedure: Biospecimen Collection
Procedure: Biopsy
Procedure: Therapeutic Conventional Surgery
First Posted Date
2021-09-01
Last Posted Date
2024-10-31
Lead Sponsor
Mayo Clinic
Target Recruit Count
25
Registration Number
NCT05030298
Locations
🇺🇸

Mayo Clinic in Florida, Jacksonville, Florida, United States

Testing the Addition of an Immunotherapy Drug, Atezolizumab, to the Usual Chemotherapy Treatment During Radiation Therapy for Superior Sulcus Non-small Cell Lung Cancer

Phase 2
Withdrawn
Conditions
Stage IIB Lung Cancer AJCC v8
Lung Non-Small Cell Carcinoma
Superior Sulcus Lung Carcinoma
Stage IIIA Lung Cancer AJCC v8
Interventions
Biological: Atezolizumab
Procedure: Biopsy
Procedure: Biospecimen Collection
Drug: Carboplatin
Procedure: Computed Tomography
Drug: Cisplatin
Drug: Etoposide
Radiation: External Beam Radiation Therapy
Procedure: Magnetic Resonance Imaging
Drug: Paclitaxel
Drug: Pemetrexed
Procedure: Positron Emission Tomography
Procedure: Therapeutic Conventional Surgery
First Posted Date
2021-08-04
Last Posted Date
2023-09-26
Lead Sponsor
National Cancer Institute (NCI)
Registration Number
NCT04989283
Locations
🇺🇸

Community Medical Hospital, Missoula, Montana, United States

🇺🇸

The Mark H Zangmeister Center, Columbus, Ohio, United States

🇺🇸

Rush - Copley Medical Center, Aurora, Illinois, United States

and more 43 locations

AL101 Before Surgery for the Treatment of Notch Activated Adenoid Cystic Cancer

Phase 1
Active, not recruiting
Conditions
Adenoid Cystic Carcinoma
Metastatic Adenoid Cystic Carcinoma
Interventions
Drug: AL101
Procedure: Therapeutic Conventional Surgery
First Posted Date
2021-07-22
Last Posted Date
2024-10-26
Lead Sponsor
M.D. Anderson Cancer Center
Target Recruit Count
14
Registration Number
NCT04973683
Locations
🇺🇸

M D Anderson Cancer Center, Houston, Texas, United States

Testing the Addition of an Anti-Cancer Immunotherapy Drug, Avelumab, to Gemcitabine and Carboplatin Chemotherapy Prior to Surgery in Muscle Invasive Urinary Tract Cancer vs. Surgery Alone in Patients Who Are Not Able to Receive Cisplatin Therapy (SWOG GAP TRIAL)

Phase 2
Terminated
Conditions
Bladder Carcinoma Infiltrating the Muscle of the Bladder Wall
Infiltrating Renal Pelvis and Ureter Urothelial Carcinoma
Stage II Bladder Cancer AJCC v8
Interventions
Procedure: Therapeutic Conventional Surgery
Drug: Avelumab
Drug: Gemcitabine Hydrochloride
Drug: Carboplatin
First Posted Date
2021-05-04
Last Posted Date
2024-12-30
Lead Sponsor
SWOG Cancer Research Network
Target Recruit Count
6
Registration Number
NCT04871529
Locations
🇺🇸

NorthShore University HealthSystem-Glenbrook Hospital, Glenview, Illinois, United States

🇺🇸

Northwestern University, Chicago, Illinois, United States

🇺🇸

Illinois CancerCare-Eureka, Eureka, Illinois, United States

and more 89 locations
© Copyright 2025. All Rights Reserved by MedPath